Cardiovascular Systems (NASDAQ: CSII) and LDR (NASDAQ:LDRH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.

Insider & Institutional Ownership

Get Cardiovascular Systems alerts:

74.2% of Cardiovascular Systems shares are held by institutional investors. 3.3% of Cardiovascular Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Cardiovascular Systems and LDR’s net margins, return on equity and return on assets.

Net Margins

Return on Equity

Return on Assets

Cardiovascular Systems

-1.62%

-0.51%

-0.31%

LDR

-18.02%

-16.37%

-13.65%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Cardiovascular Systems and LDR, as provided by MarketBeat.

Sell Ratings

Hold Ratings

Buy Ratings

Strong Buy Ratings

Rating Score

Cardiovascular Systems

1

4

1

0

2.00

LDR

0

0

0

0

N/A

Cardiovascular Systems currently has a consensus target price of $26.50, indicating a potential upside of 16.02%.

LDR has lower revenue, but higher earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than LDR, indicating that it is currently the more affordable of the two stocks.

Summary

Cardiovascular Systems beats LDR on 8 of the 9 factors compared between the two stocks.

LDR Holding Corporation is a medical device company. The Company focuses on designing and commercializing surgical technologies for the treatment of patients suffering from spine disorders. The Company’s primary products are based on its VerteBRIDGE fusion and Mobi non-fusion platforms, both of which are designed for applications in the cervical and lumbar spine. The Company’s VerteBRIDGE products are designed around its plating technology that enables surgeons to implant VerteBRIDGE devices with direct visualization of the disc and to affix the devices to the vertebrae from inside the spinal disc space. The Company’s Mobi non-fusion platform is underlined by Mobi-C, a cervical disc replacement device with a mobile bearing core that is designed to replicate the natural anatomical movement of the spine by facilitating independent bending and twisting similar to a healthy disc. The Company’s traditional fusion products include Easyspine, MC+, ROI, ROI-T, SpineTune and C-Plate.